BCSCDB: Biomarkers of Cancer Stem Cells Database
Number of entries related to U-87MG cell line is 67
| GENE | HGNC_ID | MARKER_TYPE | CANCER_TYPE | HISTOLOGICAL_TYPE | CELL_LINE | CSC_ENRICHMENT | METHOD | EXPRESSION_LEVEL | CONFIDENCE_SCORING | GLOBAL_SCORING | PUBMED_ID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CD44 | 1681 | LTM | Glioblastoma | NA | U-87MG | NA | FACs and SFA followed by Western blotting and qRT-PCR | NA | 0.6 | 1 | 34408983 |
| PROM1 | 9454 | LTM | Glioblastoma | NA | U-87MG | NA | FACs and SFA followed by Western blotting and qRT-PCR | NA | 0.6 | 0.7582 | 34408983 |
| PROM1 | 9454 | LTM | Glioblastoma | NA | U-87MG | NA | SFA and IF staining followed by qRT-PCR and FACs | NA | 0.6 | 0.7582 | 26030909 |
| PROM1 | 9454 | LTM | Glioblastoma | NA | U-87MG | NA | SFA followed by Western Blotting | NA | 0.6 | 0.7582 | 29115404 |
| PROM1 | 9454 | LTM | Glioblastoma | NA | U-87MG | NA | SFA followed by Western Blotting | NA | 0.6 | 0.7582 | 29115404 |
| PROM1 | 9454 | LTM | Glioblastoma | NA | U-87MG | NA | SFA followed by Western Blotting | NA | 0.6 | 0.7582 | 32578777 |
| PROM1 | 9454 | LTM | Glioblastoma | NA | U-87MG | Temozolomide | SFA followed by Western Blotting | NA | 0.6 | 0.7582 | 33691197 |
| PROM1 | 9454 | LTM | Glioblastoma | NA | U-87MG | NA | SFA followed by Western Blotting and Sedimentation field flow fractionation(SdFFF) | NA | 0.6 | 0.7582 | 31179686 |
| PROM1 | 9454 | LTM | Glioblastoma | NA | U-87MG | NA | Western Blotting and SFA | NA | 0.6 | 0.7582 | 31717924 |
| PROM1 | 9454 | LTM | Glioblastoma | NA | U-87MG | NA | SFA and Western Blotting | NA | 0.6 | 0.7582 | 28394339 |
| PROM1 | 9454 | LTM | Glioblastoma | NA | U-87MG | NA | SFA followed by IF staining | NA | 0.6 | 0.7582 | 25394756 |
| PROM1 | 9454 | LTM | Glioblastoma | NA | U-87MG | NA | SFA followed by IF staining | NA | 0.6 | 0.7582 | 33889875 |
| PROM1 | 9454 | LTM | Glioblastoma | NA | U-87MG | NA | IF staining followed by SFA | NA | 0.6 | 0.7582 | 21193962 |
| PROM1 | 9454 | LTM | Glioblastoma | NA | U-87MG | NA | SFA followed by RT-PCR | NA | 0.6 | 0.7582 | 31288857 |
| PROM1 | 9454 | LTM | Glioblastoma | NA | U-87MG | NA | SFA and qRT-PCR | NA | 0.6 | 0.7582 | 20082319 |
| PROM1 | 9454 | LTM | Glioblastoma | NA | U-87MG | NA | FACs followed by SFA and SP assay | NA | 0.6 | 0.7582 | 19232461 |
| PROM1 | 9454 | LTM | Glioblastoma | NA | U-87MG | NA | SFA followed by FACs | NA | 0.6 | 0.7582 | 29452949 |
| PROM1 | 9454 | LTM | Glioblastoma | NA | U-87MG | NA | SFA followed by FACs | NA | 0.6 | 0.7582 | 34235925 |
| PROM1 | 9454 | LTM | Glioblastoma | NA | U-87MG | NA | FACs followed by SFA | NA | 0.6 | 0.7582 | 28685346 |
| PROM1 | 9454 | LTM | Glioblastoma | NA | U-87MG | NA | SFA followed by FACs | NA | 0.6 | 0.7582 | 19212677 |
| NANOG | 20857 | LTM | Glioblastoma | NA | U-87MG | NA | SFA followed by Western Blotting and qRT-PCR | NA | 0.48 | 0.5461 | 34408983 |
| NANOG | 20857 | LTM | Glioblastoma | NA | U-87MG | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 29115404 |
| NANOG | 20857 | LTM | Glioblastoma | NA | U-87MG | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 32578777 |
| NANOG | 20857 | LTM | Glioblastoma | NA | U-87MG | NA | SFA and Western Blotting | NA | 0.48 | 0.5461 | 32360621 |
| NANOG | 20857 | LTM | Glioblastoma | NA | U-87MG | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 30175027 |
| POU5F1 | 9221 | LTM | Glioblastoma | NA | U-87MG | NA | SFA followed by Western Blotting and qRT-PCR | NA | 0.48 | 0.6448 | 34408983 |
| POU5F1 | 9221 | LTM | Glioblastoma | NA | U-87MG | NA | SFA followed by Western Blotting | NA | 0.48 | 0.6448 | 32578777 |
| POU5F1 | 9221 | LTM | Glioblastoma | NA | U-87MG | Temozolomide | SFA followed by Western Blotting | NA | 0.48 | 0.6448 | 33691197 |
| POU5F1 | 9221 | LTM | Glioblastoma | NA | U-87MG | NA | SFA followed by Western Blotting and Sedimentation field flow fractionation(SdFFF) | NA | 0.48 | 0.6448 | 31179686 |
| POU5F1 | 9221 | LTM | Glioblastoma | NA | U-87MG | NA | SFA and Western Blotting | NA | 0.48 | 0.6448 | 28394339 |
| POU5F1 | 9221 | LTM | Glioblastoma | NA | U-87MG | NA | SFA and Western Blotting | NA | 0.48 | 0.6448 | 29228694 |
| POU5F1 | 9221 | LTM | Glioblastoma | NA | U-87MG | NA | SFA and Western Blotting | NA | 0.48 | 0.6448 | 32360621 |
| POU5F1 | 9221 | LTM | Glioblastoma | NA | U-87MG | NA | SFA followed by IF staining | NA | 0.48 | 0.6448 | 34235925 |
| POU5F1 | 9221 | LTM | Glioblastoma | NA | U-87MG | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.6448 | 30175027 |
| SOX2 | 11195 | LTM | Glioblastoma | NA | U-87MG | NA | SFA followed by Western Blotting and qRT-PCR | NA | 0.48 | 0.5695 | 34408983 |
| SOX2 | 11195 | LTM | Glioblastoma | NA | U-87MG | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5695 | 29115404 |
| SOX2 | 11195 | LTM | Glioblastoma | NA | U-87MG | Temozolomide | SFA followed by Western Blotting | NA | 0.48 | 0.5695 | 33691197 |
| SOX2 | 11195 | LTM | Glioblastoma | NA | U-87MG | NA | Western Blotting and SFA | NA | 0.48 | 0.5695 | 31717924 |
| SOX2 | 11195 | LTM | Glioblastoma | NA | U-87MG | NA | SFA and Western Blotting | NA | 0.48 | 0.5695 | 28394339 |
| SOX2 | 11195 | LTM | Glioblastoma | NA | U-87MG | NA | SFA and Western Blotting | NA | 0.48 | 0.5695 | 29228694 |
| SOX2 | 11195 | LTM | Glioblastoma | NA | U-87MG | NA | SFA and Western Blotting | NA | 0.48 | 0.5695 | 32360621 |
| SOX2 | 11195 | LTM | Glioblastoma | NA | U-87MG | NA | SFA followed by IF staining | NA | 0.48 | 0.5695 | 34235925 |
| SOX2 | 11195 | LTM | Glioblastoma | NA | U-87MG | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5695 | 30175027 |
| SOX2 | 11195 | LTM | Glioblastoma | NA | U-87MG | NA | SFA followed by RT-PCR | NA | 0.48 | 0.5695 | 31288857 |
| SOX2 | 11195 | LTM | Glioblastoma | NA | U-87MG | NA | SFA and qRT-PCR | NA | 0.48 | 0.5695 | 20082319 |
| STAT3 | 11364 | LTM | Glioblastoma | NA | U-87MG | NA | SFA followed by Western Blotting and qRT-PCR | NA | 0.48 | 0.0223 | 34408983 |
| STAT3 | 11364 | LTM | Glioblastoma | NA | U-87MG | NA | SFA followed by Western Blotting | NA | 0.48 | 0.0223 | 29115404 |
| A2B5 | NA | LTM | Glioblastoma | NA | U-87MG | NA | SFA followed by Western Blotting and Sedimentation field flow fractionation(SdFFF) | NA | 0.28 | 0.0011 | 31179686 |
| BMI1 | 1066 | LTM | Glioblastoma | NA | U-87MG | Temozolomide | SFA followed by Western Blotting | NA | 0.28 | 0.1135 | 33691197 |
| BMI1 | 1066 | LTM | Glioblastoma | NA | U-87MG | NA | Western Blotting and SFA | NA | 0.28 | 0.1135 | 31717924 |
| HIF1A | 4910 | LTM | Glioblastoma | NA | U-87MG | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0106 | 29115404 |
| MAPK3 | 6877 | LTM | Glioblastoma | NA | U-87MG | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0032 | 29115404 |
| MET | 7029 | LTM | Glioblastoma | NA | U-87MG | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0191 | 29115404 |
| NES | 7756 | LTM | Glioblastoma | NA | U-87MG | NA | SFA and Western Blotting | NA | 0.28 | 0.0573 | 28394339 |
| NES | 7756 | LTM | Glioblastoma | NA | U-87MG | NA | SFA and Western Blotting | NA | 0.28 | 0.0573 | 29228694 |
| NES | 7756 | LTM | Glioblastoma | NA | U-87MG | NA | SFA followed by IF staining | NA | 0.28 | 0.0573 | 33889875 |
| NES | 7756 | LTM | Glioblastoma | NA | U-87MG | NA | SFA followed by IF staining | NA | 0.28 | 0.0573 | 34235925 |
| NES | 7756 | LTM | Glioblastoma | NA | U-87MG | NA | IF staining followed by SFA | NA | 0.28 | 0.0573 | 21193962 |
| NES | 7756 | LTM | Glioblastoma | NA | U-87MG | NA | SFA followed by RT-PCR | NA | 0.28 | 0.0573 | 31288857 |
| VEGF | 12680 | LTM | Glioblastoma | NA | U-87MG | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0042 | 29115404 |
| MYC | 7553 | LTM | Glioblastoma | NA | U-87MG | NA | SFA followed by IF staining | NA | 0.24 | 0.1304 | 31035045 |
| MIR21 | 31586 | LTM | Glioblastoma | NA | U-87MG | NA | SFA followed by RT-PCR | NA | 0.2 | 0.0085 | 25394756 |
| ALDH1A1 | 402 | LTM | Glioblastoma | NA | U-87MG | NA | SFA followed by ALDEFLUOR assay | NA | 0.12 | 0.684 | 31035045 |
| ALDH1A1 | 402 | LTM | Glioblastoma | NA | U-87MG | NA | ALDEFLUOR assay followed by SFA | NA | 0.12 | 0.684 | 28685346 |
| MICA | 7090 | LTM | Glioblastoma | NA | U-87MG | NA | SFA followed by FACs | NA | 0.12 | 0.0021 | 31288857 |
| NGFR | 7809 | LTM | Glioblastoma | NA | U-87MG | NA | SFA followed by FACs | NA | 0.12 | 0.018 | 30175027 |
| ULBP2 | 14894 | LTM | Glioblastoma | NA | U-87MG | NA | SFA followed by FACs | NA | 0.12 | 0.0021 | 31288857 |